^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    hIMB1636-MMAE

    i
    Other names: hIMB1636-MMAE
    Company:
    Institute of Medicinal Biotechnology
    Drug class:
    Tubulin inhibitor, TROP-2-targeted antibody-drug conjugate
    Related drugs:
    1year
    hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer. (PubMed, J Med Chem)
    It displayed significant tumor-targeting ability and excellent tumor-suppressive effects in vivo, resulting in 5/8 tumor elimination at 12 mg/kg in the T3M4 xenograft model or complete tumor disappearance at 10 mg/kg in BxPc-3 xenografts in nude mice. Its half-life in mice was about 87 h. These data suggested that hIMB1636-MMAE was a promising candidate for the treatment of pancreatic cancer with TROP2 overexpression.
    Journal
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    TROP2 expression • TROP2 overexpression
    |
    hIMB1636-MMAE